The immune response mediated by Th17 cells is essential in the pathogenesis of periodontitis. Emerging evidence has demonstrated that lipopolysaccharide from Porphyromonas gingivalis (Pg-LPS) could promote Th17-cell differentiation directly, while the downstream signaling remains elusive. This study was aimed to explore the role of JMJD3 (a JmjC family histone demethylase) and signal transducers and activators of transcription 3 (STAT3) in Th17-cell differentiation triggered by Pg-LPS and clarify the interaction between them. We found that the expression of JMJD3 and STAT3 was significantly increased under Th17-polarizing conditions. Pg-LPS could promote Th17-cell differentiation from CD4+ T cells, with an increased expression of JMJD3 and STAT3 compared to the culture without Pg-LPS. The coimmunoprecipitation results showed that the interactions of JMJD3 and STAT3, STAT3 and retinoid-related orphan nuclear receptor γt (RORγt) were enhanced following Pg-LPS stimulation during Th17-cell differentiation. Further blocking assays were performed and the results showed that inhibition of STAT3 or JMJD3 both suppressed the Th17-cell differentiation, JMJD3 inhibitor could reduce the expression of STAT3 and p-STAT3, while JMJD3 expression was not affected when STAT3 was inhibited. Taken together, this study found that JMJD3 could promote Pg-LPS induced Th17-cell differentiation by modulating the STAT3-RORc signaling pathway.
Get full access to this article
View all access options for this article.
References
1.
AdibradM., DeyhimiP., Ganjalikhani HakemiM., BehfarniaP., ShahabueiM., and RafieeL. (2012). Signs of the presence of Th17 cells in chronic periodontal disease. J Periodontal Res, 47, 525–531.
2.
AugustA. (2018). Who regulates whom: ZNF341 is an additional player in the STAT3/T(H)17 song. Sci Immunol 3,eaat9779.
3.
BoccasaviaV.L., BovolentaE.R., VillanuevaA., BorrotoA., OesteC.L., van SantenH.M., et al. (2021). Antigen presentation between T cells drives Th17 polarization under conditions of limiting antigen. Cell Rep 34,108861.
4.
BurchfieldJ.S., LiQ., WangH.Y., and WangR.F. (2015). JMJD3 as an epigenetic regulator in development and disease. Int J Biochem Cell Biol, 67, 148–157.
5.
CandelliM., FranzaL., PignataroG., OjettiV., CovinoM., PiccioniA., et al. (2021). Interaction between lipopolysaccharide and gut microbiota in inflammatory bowel diseases. Int J Mol Sci 22,6242.
6.
CekiciA., KantarciA., HasturkH., and Van DykeT.E. (2014). Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontol 2000, 64, 57–80.
7.
ChenL.P., CaiM., ZhangQ.H., LiZ.L., QianY.Y., BaiH.W., et al. (2009). Activation of interleukin-6/STAT3 in rat cholangiocyte proliferation induced by lipopolysaccharide. Dig Dis Sci, 54, 547–554.
8.
ChengW.C., van AstenS.D., BurnsL.A., EvansH.G., WalterG.J., HashimA., et al. (2016). Periodontitis-associated pathogens P. gingivalis and A. actinomycetemcomitans activate human CD14(+) monocytes leading to enhanced Th17/IL-17 responses. Eur J Immunol, 46, 2211–2221.
9.
CiesielskaA., MatyjekM., and KwiatkowskaK. (2021). TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell Mol Life Sci, 78, 1233–1261.
10.
CiofaniM., MadarA., GalanC., SellarsM., MaceK., PauliF., et al. (2012). A validated regulatory network for Th17 cell specification. Cell, 151, 289–303.
11.
De SantaF., NarangV., YapZ.H., TusiB.K., BurgoldT., AustenaaL., et al. (2009). Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J, 28, 3341–3352.
12.
DiasA.S.O., SacramentoP.M., LopesL.M., SalesM.C., CastroC., AraújoA., et al. (2019). TLR-2 and TLR-4 agonists favor expansion of CD4(+) T cell subsets implicated in the severity of neuromyelitis optica spectrum disorders. Mult Scler Relat Disord, 34, 66–76.
13.
DingY., YaoY., GongX., ZhuoQ., ChenJ., TianM., et al. (2021). JMJD3: a critical epigenetic regulator in stem cell fate. Cell Commun Signal 19,72.
14.
DurantL., WatfordW.T., RamosH.L., LaurenceA., VahediG., WeiL., et al. (2010). Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity, 32, 605–615.
15.
EskanM.A., JotwaniR., AbeT., ChmelarJ., LimJ.H., LiangS., et al. (2012). The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat Immunol, 13, 465–473.
16.
HeimM.H. (1996). The Jak-STAT pathway: specific signal transduction from the cell membrane to the nucleus. Eur J Clin Invest, 26, 1–12.
17.
HeinbockelL., WeindlG., Martinez-de-TejadaG., CorreaW., Sanchez-GomezS., Bárcena-VarelaS., et al. (2018). Inhibition of lipopolysaccharide- and lipoprotein-induced inflammation by antitoxin peptide Pep19-2.5. Front Immunol 9,1704.
18.
HeinrichP.C., BehrmannI., Müller-NewenG., SchaperF., and GraeveL. (1998). Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J, 334, 297–314.
19.
IvanovII., McKenzieB.S., ZhouL., TadokoroC.E., LepelleyA., LafailleJ.J., et al. (2006). The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell, 126, 1121–1133.
20.
JohnsonD.E., O'KeefeR.A., and GrandisJ.R. (2018). Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol, 15, 234–248.
21.
KidderB.L., YangJ., and PalmerS. (2008). Stat3 and c-Myc genome-wide promoter occupancy in embryonic stem cells. PLoS One 3,e3932.
22.
KitamuraH., OhnoY., ToyoshimaY., OhtakeJ., HommaS., KawamuraH., et al. (2017). Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci, 108, 1947–1952.
23.
KönönenE., GursoyM., and GursoyU.K. (2019). Periodontitis: a multifaceted disease of tooth-supporting tissues. J Clin Med 8,1135.
24.
LaMereS.A., ThompsonR.C., MengX., KomoriH.K., MarkA., and SalomonD.R. (2017). H3K27 Methylation dynamics during CD4 T cell activation: regulation of JAK/STAT and IL12RB2 expression by JMJD3. J Immunol, 199, 3158–3175.
25.
LiR., WangJ., ZhuF., LiR., LiuB., XuW., et al. (2018). HMGB1 regulates T helper 2 and T helper17 cell differentiation both directly and indirectly in asthmatic mice. Mol Immunol, 97, 45–55.
26.
LiuZ., CaoW., XuL., ChenX., ZhanY., YangQ., et al. (2015). The histone H3 lysine-27 demethylase Jmjd3 plays a critical role in specific regulation of Th17 cell differentiation. J Mol Cell Biol, 7, 505–516.
MillsK.H. (2011). TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol, 11, 807–822.
31.
MoutsopoulosN.M., KonkelJ., SarmadiM., EskanM.A., WildT., DutzanN., et al. (2014). Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. Sci Transl Med 6,229ra240.
32.
ParkD.W., LyuJ.H., KimJ.S., ChinH., BaeY.S., and BaekS.H. (2013). Role of JAK2-STAT3 in TLR2-mediated tissue factor expression. J Cell Biochem, 114, 1315–1321.
33.
ParkJ.H., JeongS.Y., ChoiA.J., and KimS.J. (2015). Lipopolysaccharide directly stimulates Th17 differentiation in vitro modulating phosphorylation of RelB and NF-κB1. Immunol Lett, 165, 10–19.
34.
PencikJ., PhamH.T., SchmoellerlJ., JavaheriT., SchledererM., CuligZ., et al. (2016). JAK-STAT signaling in cancer: from cytokines to non-coding genome. Cytokine, 87, 26–36.
35.
PrzanowskiP., DabrowskiM., Ellert-MiklaszewskaA., KlossM., MieczkowskiJ., KazaB., et al. (2014). The signal transducers Stat1 and Stat3 and their novel target Jmjd3 drive the expression of inflammatory genes in microglia. J Mol Med (Berl), 92, 239–254.
36.
RussB.E., OlshanksyM., SmallwoodH.S., LiJ., DentonA.E., PrierJ.E., et al. (2014). Distinct epigenetic signatures delineate transcriptional programs during virus-specific CD8(+) T cell differentiation. Immunity, 41, 853–865.
37.
SallustoF. (2016). Heterogeneity of human CD4(+) T cells against microbes. Annu Rev Immunol, 34, 317–334.
38.
SalminenA., KaarnirantaK., HiltunenM., and KauppinenA. (2014). Histone demethylase Jumonji D3 (JMJD3/KDM6B) at the nexus of epigenetic regulation of inflammation and the aging process. J Mol Med (Berl), 92, 1035–1043.
39.
Sherry-LynesM.M., SenguptaS., KulkarniS., and CochranB.H. (2017). Regulation of the JMJD3 (KDM6B) histone demethylase in glioblastoma stem cells by STAT3. PLoS One 12,e0174775.
40.
TripathiS.K., ChenZ., LarjoA., KanduriK., NousiainenK., ÄijoT., et al. (2017). Genome-wide analysis of STAT3-mediated transcription during early human Th17 cell differentiation. Cell Rep, 19, 1888–1901.
41.
VillarinoA.V., KannoY., FerdinandJ.R., and O'SheaJ.J. (2015). Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol, 194, 21–27.
42.
WangX., ZhangY., YangX.O., NurievaR.I., ChangS.H., OjedaS.S., et al. (2012). Transcription of Il17 and Il17f is controlled by conserved noncoding sequence 2. Immunity, 36, 23–31.
43.
WeiG., WeiL., ZhuJ., ZangC., Hu-LiJ., YaoZ., et al. (2009). Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity, 30, 155–167.
44.
WilsonR.H., WhiteheadG.S., NakanoH., FreeM.E., KollsJ.K., and CookD.N. (2009). Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness. Am J Respir Crit Care Med, 180, 720–730.
45.
WuX., ShouQ., ChenC., CaiH., ZhangJ., TangS., et al. (2017). An herbal formula attenuates collagen-induced arthritis via inhibition of JAK2-STAT3 signaling and regulation of Th17 cells in mice. Oncotarget, 8, 44242–44254.
46.
YangJ., ZhaoY., and ShaoF. (2015). Non-canonical activation of inflammatory caspases by cytosolic LPS in innate immunity. Curr Opin Immunol, 32, 78–83.
47.
YinX., ChenS., and EisenbarthS.C. (2021). Dendritic cell regulation of T helper cells. Annu Rev Immunol, 39, 759–790.
48.
YuH., PardollD., and JoveR. (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer, 9, 798–809.
49.
ZeinalzadehE., Valerievich YumashevA., RahmanH.S., MarofiF., ShomaliN., KafilH.S., et al. (2021). The role of Janus Kinase/STAT3 pathway in hematologic malignancies with an emphasis on epigenetics. Front Genet 12,703883.
50.
ZengX.Z., ZhangY.Y., YangQ., WangS., ZouB.H., TanY.H., et al. (2020). Artesunate attenuates LPS-induced osteoclastogenesis by suppressing TLR4/TRAF6 and PLCγ1-Ca(2+)-NFATc1 signaling pathway. Acta Pharmacol Sin, 41, 229–236.
51.
ZhangC., XuC., GaoL., LiX., and ZhaoC. (2021). Porphyromonas gingivalis lipopolysaccharide promotes T-hel per17 cell differentiation by upregulating Delta-like ligand 4 expression on CD14(+) monocytes. PeerJ 9,e11094.
52.
ZhangJ.A., MortazaviA., WilliamsB.A., WoldB.J., and RothenbergE.V. (2012). Dynamic transformations of genome-wide epigenetic marking and transcriptional control establish T cell identity. Cell, 149, 467–482.
53.
ZhangL., GaoL., XuC., LiX., WangP., ZhangC., et al. (2019a). Porphyromonas gingivalis lipopolysaccharide promotes T- helper 17 cell differentiation from human CD4(+) naive T cells via toll-like receptor-2 in vitro. Arch Oral Biol 107,104483.
54.
ZhangX., LiuL., YuanX., WeiY., and WeiX. (2019b). JMJD3 in the regulation of human diseases. Protein Cell, 10, 864–882.
55.
ZhaoM., TanY., PengQ., HuangC., GuoY., LiangG., et al. (2018). IL-6/STAT3 pathway induced deficiency of RFX1 contributes to Th17-dependent autoimmune diseases via epigenetic regulation. Nat Commun 9,583.
56.
ZhengY., MingP., ZhuC., SiY., XuS., ChenA., et al. (2019). Hepatitis B virus X protein-induced SH2 domain-containing 5 (SH2D5) expression promotes hepatoma cell growth via an SH2D5-transketolase interaction. J Biol Chem, 294, 4815–4827.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
